Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study to evaluate both double combinations buntanetap with GLP-1 agonist or PDE5 inhibitor

Next Previous
Trial Profile

A phase III study to evaluate both double combinations buntanetap with GLP-1 agonist or PDE5 inhibitor

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 09 Apr 2026 According to Annovis Bio media release, company announced $10 Million underwritten Offering of Common Stock.Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimers disease.
  • 24 Nov 2025 According to Annovis Bio Inc, the study design will be presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California.
  • 13 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top